FDA expands indication for asthma rescue inhaler to younger patients – Healio

FDA expands indication for asthma rescue inhaler to younger patients
Healio
Teva Pharmaceuticals announced today that the FDA has expanded the indication for its ProAir, RespiClick inhalation powder to include patients with asthma aged 4 to 11 years, according to a press release.
Teva Pharma (TEVA) Receives FDA Approval for ProAir RespiClick for Pediatric Asthma Patients Ages 4 to 11StreetInsider.com
FDA Expands Breath-Actuated Inhaler Use to Kids as Young as 4Medscape

all 5 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *